Autolus Therapeutics (AUTL) Cash from Financing Activities (2017 - 2025)

Autolus Therapeutics' Cash from Financing Activities history spans 5 years, with the latest figure at -$1.8 million for Q4 2025.

  • For Q4 2025, Cash from Financing Activities fell 105.99% year-over-year to -$1.8 million; the TTM value through Dec 2025 reached -$4.3 million, down 100.74%, while the annual FY2025 figure was -$4.3 million, 100.74% down from the prior year.
  • Cash from Financing Activities reached -$1.8 million in Q4 2025 per AUTL's latest filing, down from -$1.8 million in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $561.4 million in Q1 2024 to a low of -$2.1 million in Q2 2024.
  • Average Cash from Financing Activities over 4 years is $67.3 million, with a median of -$107500.0 recorded in 2023.
  • Peak YoY movement for Cash from Financing Activities: surged 130365.22% in 2024, then crashed 1058.92% in 2025.
  • A 4-year view of Cash from Financing Activities shows it stood at $223.5 million in 2022, then tumbled by 99.99% to $23000.0 in 2023, then soared by 130365.22% to $30.0 million in 2024, then plummeted by 105.99% to -$1.8 million in 2025.
  • Per Business Quant, the three most recent readings for AUTL's Cash from Financing Activities are -$1.8 million (Q4 2025), -$1.8 million (Q3 2025), and -$768000.0 (Q2 2025).